PLRZ enters the back half of May with a clinical catalyst in hand — and a borrow market that has swung from near-maximum tightness to near-total availability in the space of a fortnight.
The catalyst is concrete. Polyrizon signed a clinical trial agreement this week with a U.S. research site specialising in allergy studies, advancing its NASARIX allergy-blocker programme. That followed a May 4 amendment to U.S. patent claims on the company's intranasal drug delivery platform, and a European patent filing the week prior. Three pipeline-related announcements in under three weeks is an unusually busy run for a micro-cap biotech with a market cap of roughly $28 million. The stock reflects it: up 39% over the past month, and another 6% higher on the week, even after pulling back 6.9% on Tuesday.
The most striking data point this week is how sharply the lending picture has changed. A month ago, availability was extremely tight — utilization was running at 75-100% through most of April, with borrowing costs holding above 420% APR through late April and into early May. That is a market under real squeeze pressure. Now, availability has swung to effectively unlimited: the borrow pool is nearly empty of short demand, with utilization at just 0.04% as of Tuesday. Short interest itself fell 20% on the week and 36% over the past month, landing near 32,600 shares. At roughly 2% of free float, it is a modest position. Borrowing costs have eased too — still extreme at 375% APR, but well below the 500%-plus levels seen in late March and early April. The message is clear: shorts that crowded in during April have largely exited, and new shorts have not replaced them.
The ORTEX short score has moved accordingly. It dropped from 64 at the start of the month to 43.7 by May 12 — a meaningful step back from what was a genuinely elevated reading. The days-to-cover rank of 88 and utilization rank of 84 are legacy artifacts of the tighter April environment; the live readings suggest those pressures have dissipated. With no analyst coverage to speak of and no meaningful valuation multiples to anchor the stock — enterprise value is a slim $6.8 million against a $15 stock price, pointing to a heavily cash-dependent balance sheet — the trading story here is driven entirely by newsflow and positioning, not fundamentals.
Institutional ownership is thin and concentrated. MM Asset Management holds 7.3% of shares, the only institutional name with a material stake. Several individuals on the registry — including the CEO Tomer Izraeli — appear as holders, and the insider register shows a cluster of small sales at prices of $10.90–$12.36 back in late March. Those trades carried low significance scores and involved modest sums; they predate the latest news cycle and the price is now well above those levels.
The next scheduled event is a June 17 earnings release. Past post-earnings moves have been mixed: a 1.3% gain the day after March's print but a 7% five-day decline, versus a 12.6% one-day rally and 17.4% five-day gain after December's report. With the stock up nearly 40% in a month driven by patent and clinical newsflow rather than earnings, the June print will be watched more for any update on NASARIX trial timelines than for the financial figures themselves.
See the live data behind this article on ORTEX.
Open PLRZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
